Accelerating Medical Innovation
To Enhance Patient Wellbeing
PBC Biomed was founded in 2010 to drive innovation in Medical Devices, Biomaterials and Pharmaceuticals by helping clients accelerate the commercialization of ideas. Our extensive industry expertise has made us the trusted strategic partner for small to large companies, physicians, universities and government-funded projects to advance the development of life-changing medical technologies.
A Partner you can Trust.
We are passionate about our advancing MedTech, and the impact we can make on patients lives by accelerating innovation within this space.
We take pride in our ability to provide the best resources, technical capabilities and quality of work, by utilising our extensive expertise in the Design, Development and Commercialisation of innovative medical technologies.
PBC Biomed is certified to both ISO 9001,2015 for the provision of Consultancy Services and ISO 13485, 2016 for Design. Development and Manufacture of Bone Substitute materials.
News & Publications
-
PBC BioMed announces launch of new innovation management tool ‘AIM’.
With an established track record of innovation, PBC BioMed has assembled a global team with a deep understanding of the regulatory, quality, clinical and commercial requirements facing innovators based in the EU or US, and wishing to enter new markets.
-
PBC Biomed recognised for contribution to Athlete Friendly Employer (AFE) programme by Sport Ireland.
PBC Biomed were delighted to attend the Athlete Friendly Employer (AFE) Networking Breakfast, which took place at the heart of high-performance sport on the Sport Ireland Campus in Dublin last Friday. We were proud to be presented with a certificate of #recognition for our contribution to the AFE programme on the day. Pictured from left to right below is three-time…
-
PBC Biomed Clinical Advisory Board publish Editorial in Injury Journal.
Part One of our ‘Strengthening the Bond’ symposium series at the Orthopaedic Trauma Association meeting in Tampa, focused on the unanswered challenges of osteosynthesis, as well as a first look at research on a promising new bio-adhesive. This surgeon panel, consisting of Professor Peter Giannoudis, Dr Tracy Watson, Dr Thomas A Russell, Dr Hassan Mir…
-
David Kelly, Research Scientist, celebrates 10 years with PBC Biomed.
Congratulations to one of PBC Biomed‘s longest standing team members David Kelly, on celebrating 10 years with the company last week. Always ready to offer his insight and support, David has become a critical part of the R&D team since he joined the company a decade ago. Pictured is PBC Biomed’s CSO Gerard Insley, presenting David with his…
-
PBC Biomed Team in Memphis, February 2024.
The PBC Biomed team are in Memphis this week, introducing our new Business Development manager David Sharp to our local network! If you are in the Downtown Memphis area and would like to say hi to David, Brittney, Elaine or Pierse, please feel free to stop by our office at Epicenter Memphis. The team will be there when they’re not sampling the local cuisine! #memphis#USoffice#newhire#businessdevelopment#pbcbiomed
-
DTIF-funded project, OsStic® technology awarded #BreakthroughDevice designation by the FDA.
Shannon, Ireland, February 12th 2024: Irish medical device company Biomimetic Innovations Ltd, an affiliate of PBC Biomed, announced ‘Breakthrough Device’ designation from the Food and Drug Administration FDA in January, for the development of a groundbreaking new bio-adhesive bone void filler technology called OsStic®. PBC Biomed leads a consortium for this development project, which is…
-
New Hire: David Sharp, US Business Development Lead.
A very warm welcome to the newest member of the PBC Biomed team David Sharp, who has just joined as our US Business Development lead. David spent some time in our Irish headquarters this week to meet the extended team, however he will be based out of our US office at Epicenter Memphis. During his 25+ years working within…
-
FDA grants global Medical Device company Biomimetic Innovations ‘Breakthrough Device’ designation for OsStic® Synthetic Injectable Structural Bio-Adhesive Bone Void Filler.Â
Shannon, Ireland, 19th January, 2024: Biomimetic Innovations Ltd today announced that OsStic® has been granted ‘Breakthrough Device’ designation by the FDA. The proposed indication statement for this novel new technology is; ” OsStic®Synthetic Injectable Bone Void Filler is a structural, mechanically enhanced bioadhesive for reduction, provisional fixation, or void filling of peri-articular fractures or defects…
-
2024: A Transformative Year Ahead for PBC Biomed
Driven by our dedicated team as well as our valued industry and academic partners, 2024 is set to become a transformative year for our commercialisation and developmental programmes. We would like to take this opportunity to thank our current partners and friends for your continued support and encouragement – we look forward to sharing further…
Upcoming Events
Orthopaedic Design & Technology (ODT) Forum ’24
Our US PBC Biomed team members will attend the ODT meeting in Memphis this year, more than one year on from opening….
Orthopaedic Trauma Association (OTA) Annual Meeting​ ’24
Part 3 of the PBC Biomed ‘Provisional Fixation’ Education Programme is scheduled to take place at OTA 2024…
Orthopaedic Manufacturing & Technology Exposition & Conference (OMTEC) ’24
Join us in Chicago for the 2024 OMTEC event, which will provide an opportunity to connect with some of our key R&D and commercial team members…
European Society of Tissue Regeneration in Orthopaedics & Traumatology (ESTROT) ’24
The 8th annual ESTRO Congress to scheduled to take place in Helsinki, Finland from 10-12th June. This year, the programme focuses on…
Our Trusted Partners
PBC Biomed is the Marketing Authorization Holder for: Nelsons® Arnicare® Arnica Cream, Nelsons® Teetha® Teething Granules, & Nelsons® Teetha® Teething Gel.